The Pharma Data

AUGUST 15, 2021

Food and Drug Administration were based on mRNA, more conventional protein-based vaccines have also shown promise in clinical trials. Most train the immune system to recognize the RBD, a peptide that is the portion of the SARS-CoV-2 spike protein that binds to the ACE-2 receptor on host cell surfaces. bioRxiv [Preprint].

Protein 52

Protein Vaccination Vaccine Antibody 52

Bioengineer

JANUARY 16, 2024

This mutation hinders the drug’s binding to the mutant EGFR protein. Osimertinib, however, can covalently bind to the T790M and cysteine-797 (C797) residue at the protein’s ATP binding site, overcoming resistance mechanisms. In the same study, those with T790M loss had a shorter treatment duration (6.1 months vs. 15.2

Genome 119

Genome Genomics Protein In-Vitro 119

XTalks

JANUARY 6, 2021

One nanobody in particular, called NIH-CoVnb-112, was shown to be able to prevent COVID-19 infection from the novel coronavirus by targeting both the spike protein on SARS-CoV-2, as well as the angiotensin converting enzyme 2 (ACE2) receptor that it binds to on human cells. The study was led by neuroscientists Thomas J. “TJ”

Antibody 105

Antibody Protein Bacteria In-Vitro 105

Pharmaceutical Technology

AUGUST 11, 2022

Further in vitro studies demonstrated that the most common variant that caused a loss in INHBE function was linked to a significant reduction in the secretion of the Activin E protein.

Gene 130

Gene Biobanking Gene Expression In-Vitro 130

XTalks

JULY 22, 2021

We’ve heard of cell-based meat — meat produced by in vitro cell cultures of animal cells — but its seafood equivalent could be on the horizon. Cell-based fish has been making a splash in recent years, with several alt-seafood companies making the semi-finals of a recent alternative protein competition. Benefits of Cell-Based Fish.

Protein 96

Protein In-Vitro Production Marketing 96

Pharmaceutical Technology

FEBRUARY 23, 2023

Many compounds present sub-optimal pharmacokinetic (PK) data (either predicted from in-vitro and pre-clinical data or measured in the clinic), such as poor exposure (leading to high doses), large variability, short half-life requiring more than once-a-day dosing, or C max -related adverse events (AEs).

Development 246

Development Drugs Bioavailability In-Vivo 246

pharmaphorum

DECEMBER 1, 2022

Exploring the implementation of complex in-vitro models for drug development. The pharmaceutical industry globally is realising the growing potential of in vitro tissue models for drug discovery, pathology modelling and validation, safety and toxicity. Billion by 2028. Billion by 2028. Event Hashtag: #3DCellCulture2023.

In-Vitro 52

In-Vitro Scientist Engineer Gene Therapy 52

pharmaphorum

MARCH 1, 2021

COVID-19 antigen tests diagnose active infection by detecting SARS-CoV-2 viral proteins in samples, as opposed to PCR tests which detect viral RNA and require lab processing, but can miss infections with low virus levels. The test – which can also be self-collected – showed a sensitivity of 93.8%

In-Vitro 98

In-Vitro RNA Protein Antibody 98

BioTech 365

NOVEMBER 11, 2020

CREATES UNIQUE CO-LOCATED, FULLY-INTEGRATED, HIGH-CAPACITY R&D CENTRE ADDS IN VITRO PHARMACOLOGY AND EXPANDS PROTEIN SCIENCES CREATES CENTRE OF EXCELLENCE … Continue reading → DGAP-News: Evotec SE / Key word(s): Miscellaneous 12.11.2020 / 07:30 The issuer is solely responsible for the content of this announcement.

In-Vitro 40

In-Vitro Protein 40

Roots Analysis

AUGUST 7, 2023

On the other hand, cell free system / cell free expression system are ­in-vitro platforms that harness the transcription and translation machinery of living cells, in the form of cell lysates, to synthesize various types of biologics, particularly proteins. Interestingly, most of these kits are used for cell-free protein expression.

Marketing 52

Marketing Protein In-Vitro Production 52

XTalks

APRIL 22, 2022

Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. Flow cytometric receptor occupancy assays are being increasingly used in preclinical and clinical studies. What is Flow Cytometry?

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

XTalks

APRIL 6, 2022

Register for this webinar to get an overview of the role of long non-protein coding RNAs (lncRNAs) in gene regulations. The personalized ctDNA blood test uses the RaDaR™ assay, a liquid biopsy platform developed by the company Inivata. Photo source: Inivata. Around 85 percent of cases are non-small cell lung cancer (NSCLC).

DNA 105

DNA In-Vitro Doctors Doctor 105

XTalks

JUNE 30, 2022

Collagen is an abundant structural protein in animals. Some standard methods that augment wound healing are antimicrobial dressings, autolytic and chemical debridement, grafting and absorbent dressings for wounds that exudate. The pivotal role of collagen is for structural support of the extracellular space of connective tissue.

In-Vitro 98

In-Vitro Production Marketing Medicine 98

pharmaphorum

JANUARY 18, 2022

Developing Complex, Translatable and Physiologically-Relevant Cellular Models in vitro. Key Benefits of Attending: • Discuss the uses of advanced cell technologies to construct in vitro models of human tissues. Academia Professor – Cell Technology, Stem Cell Sciences, Biochemistry, Protein Technology and Tissue Engineering.

In-Vitro 52

In-Vitro Engineer Drugs Pharma Companies 52

The Pharma Data

JANUARY 27, 2021

Eurofins Discovery will be conducting the IND-enabling in-vitro preclinical primary pharmacology and safety pharmacology studies on TD-0148A at its state-of-the-art facilities at Eurofins Cerep, DiscoverX and Panlabs. FDA Investigational New Drug (“IND”)-enabling pharmacology studies. About BetterLife Pharma: BetterLife Pharma Inc.

In-Vitro 52

In-Vitro Containment Drugs Production 52

XTalks

JANUARY 27, 2021

The company used in vitro neutralization antibody studies to evaluate the activity of Moderna’s vaccine-generated antibodies in human sera against several variants of the novel coronavirus, including the B.1.1.7 The in vitro study evaluated the ability of mRNA-1273-generated antibodies to neutralize the new SARS-CoV-2 variants.

Vaccine 52

Vaccine Vaccination In-Vitro Protein 52

The Pharma Data

APRIL 7, 2021

today announced the launch of the Elecsys Anti-p53 immunoassay for the in vitro quantitative determination of anti-p53 antibodies. p53 is protein which, when active, helps to regulate processes which stop tumors from developing. p53 is protein which, when active, helps to regulate processes which stop tumors from developing.

In-Vitro 52

In-Vitro Antibody Genetics Protein 52

Roots Analysis

MARCH 16, 2023

It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein. In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent.

Vaccination 52

Vaccination Vaccine DNA Protein 52

The Pharma Data

JANUARY 31, 2021

Ion channels represent a large but under-exploited class of drug targets beyond G protein-coupled proteins (GPCRs). Ion channels are a class of integral membrane proteins that regulate the flow of ions across the cell membrane as a means of conducting signals between cells and their environment.

Drugs 52

Drugs Protein In-Vitro Development 52

XTalks

JANUARY 21, 2022

With the Omicron variant of SARS-CoV-2 continuing to run rampant, Italian in vitro diagnostics (IVD) company A.Menarini Diagnostics has unveiled a new real-time (RT)-PCR-based test that can detect several variants of the coronavirus including Omicron and Delta. We are extremely proud to have made this unique solution available so quickly.

RNA 69

RNA In-Vitro Protein Gene 69

The Pharma Data

APRIL 29, 2022

About Evrysdi® (risdiplam) Evrysdi is a survival motor neuron 2 (SMN2) splicing modifier designed to treat SMA caused by mutations in chromosome 5q that lead to SMN protein deficiency. Evrysdi is designed to treat SMA by increasing and sustaining the production of the SMN protein in the central nervous system (CNS) and peripheral tissues.

Protein 52

Protein In-Vitro Medicine Development 52

The Pharma Data

MAY 31, 2022

About Evrysdi® (risdiplam) Evrysdi is a survival motor neuron 2 (SMN2) splicing modifier designed to treat SMA caused by mutations in chromosome 5q that lead to SMN protein deficiency. Evrysdi is now approved in the US to treat SMA in children and adults of all ages. Jude Children’s Research Hospital.

FDA Approval 52

FDA Approval Protein In-Vitro Medicine 52

The Pharma Data

JANUARY 6, 2021

Following in vitro validation of therapeutic mechanisms, efficacy studies were conducted in mice, guinea pigs and rhesus macaque monkeys. In particular, the presynaptic localization of LC suggests this therapeutic approach will be particularly effective in treating synaptopathies involving active zone proteins.

Medicine 52

Medicine Antibody Protein In-Vitro 52

The Pharma Data

JANUARY 12, 2021

The LumiraDx SARS-CoV-2 Antigen Test uses Fast Microfluidic Immunofluorescence (FMI) technology to detect antigen nucleocapsid protein from nasal or nasopharyngeal swabs with high sensitivity results in 12 minutes. LONDON , Jan. Test specificity was 99.5% in nasal swab specimens. in nasal samples and 97.8% in nasopharyngeal samples.

In-Vitro 52

In-Vitro Protein Scientist Manufacturing 52

The Pharma Data

DECEMBER 14, 2020

The antibody targets a specific conserved region of the SARS-CoV-2 spike protein. The fully human, non-blocking antibody, 49F1, targets a specific region of the SARS-CoV-2 spike protein. The product is designed for the prevention and treatment of COVID-19, along with related coronaviruses. before expanding it into Europe.

Antibody 52

Antibody Licensing Licensing In-Vitro 52

XTalks

AUGUST 8, 2024

Tecelra works by using the patient’s own immune system to target tumors expressing the melanoma-associated antigen A4 (MAGE-A4) protein on cancer cells. Tecelra is the first cell therapy engineered for a solid tumor cancer in the US, offering a new option for patients with specific genetic markers who have previously undergone chemotherapy.

Engineer 52

Engineer Clinical Trials Clinical Trials FDA Approval 52

Delveinsight

JANUARY 18, 2021

However, DelveInsight’s Angelman syndrome market analysis report estimates that several approaches focused primarily on the Gene Therapies, Topoisomerase Inhibitors, Cannabidiol, Protein Phosphatase 2A inhibitor, among others are under development to find a cure for the Angelman syndrome. GeneTx and Ultragenyx are co-developing the therapy.

Marketing 52

Marketing Gene Drugs Protein 52

Roots Analysis

NOVEMBER 30, 2021

Most of the facilities are providing in vitro bioassay services for cell and gene therapies. Over the past few years, investigational new drug (IND) filings for cell and gene therapy product have significantly increased. Bioassays are biochemical procedures that are used to evaluate the potency, purity and efficacy of a drug substance.

Bioassay 52

Bioassay Gene Therapy Gene Development 52

XTalks

APRIL 18, 2024

The Elecsys pTau217 assay is designed to detect amyloid pathology, a hallmark of Alzheimer’s disease, by measuring phosphorylated tau protein in human plasma. A positive result on the test indicates a high likelihood of amyloid presence, as confirmed by amyloid PET scans or cerebrospinal fluid (CSF) testing.

Clinical Trials 52

Clinical Trials Clinical Trials In-Vitro Protein 52

pharmaphorum

NOVEMBER 9, 2022

Meanwhile, NRG’s in vitro studies have shown its INDs to protect mitochondria and increase the viability of human cells, potentially able to halt or significantly slow progression of diseases such as Parkinson’s and ALS. In ALS , the protein TDP-43 triggers neuroinflammation via activation of the innate immune sensor STING.

In-Vitro 52

In-Vitro Bioavailability Medicine Clinical Trials 52

FDA Law Blog

MARCH 16, 2023

This device is indicated for the following use: for the rapid, qualitative detection of SARS-CoV-2 nucleocapsid protein antigens directly in anterior nasal swab specimens from individuals with signs and symptoms of upper respiratory infection (i.e., symptomatic) when testing is started within 6 days of symptom onset.

Marketing 40

Marketing In-Vitro Regulation Reagent 40

Roots Analysis

AUGUST 12, 2024

It is worth mentioning that molecular diagnostics is a subset of the broader in vitro diagnostics market. According to the World Health Organization, there are over 40,000 in vitro diagnostics products available in the market. This vast array of products highlights the critical role of diagnostics in healthcare.

Genetics 40

Genetics Gene Expression RNA DNA 40

The Pharma Data

JANUARY 20, 2021

The LumiraDx SARS-CoV-2 Antigen Test is authorized for use by FDA under an Emergency Use Authorization (EUA) only for the detection of SARS-CoV-2 nucleocapsid protein. The LumiraDx SARS-CoV-2 Antigen Test is authorized for use by FDA under an Emergency Use Authorization (EUA) only for the detection of SARS-CoV-2 nucleocapsid protein.

In-Vitro 52

In-Vitro Protein Scientist Manufacturing 52

The Pharma Data

NOVEMBER 1, 2020

The first shipment of 1.2 million SARS-CoV-2 Assays for use on the BD Veritor Plus System to be delivered in The Netherlands by mid-November. THE HAGUE, NETHERLANDS and FRANKLIN LAKES, N.J. , THE HAGUE, NETHERLANDS and FRANKLIN LAKES, N.J. , The first 1.2 million units will be delivered by mid-November. Food and Drug Administration (FDA).

In-Vitro 52

In-Vitro Production Protein Scientist 52

Druggist

FEBRUARY 17, 2021

For many customers, ointment or cream for insect bites is the first line of rescue in stings management. In this post, I will review the best ointment or cream for insect bites available over the counter and from pharmacies. I will also discuss alternative options for insect bites, mainly the use of antihistamines. 822 Reviews. £3.19.

Pharmacy 98

Pharmacy Containment Production Sales 98

The Pharma Data

NOVEMBER 11, 2020

ADDS IN VITRO PHARMACOLOGY AND EXPANDS PROTEIN SCIENCES. CREATES UNIQUE CO-LOCATED, FULLY-INTEGRATED, HIGH-CAPACITY R&D CENTRE. CREATES CENTRE OF EXCELLENCE FOR STRUCTURE-BASED DRUG DESIGN. ” About Dorothy Crowfoot Hodgkin Dorothy Hodgkin (née Crowfoot) was born in Cairo in 1910.

In-Vitro 40

In-Vitro Insulin Development Containment 40

The Pharma Data

SEPTEMBER 1, 2020

Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions. Antigen test accurately screens individuals with known exposure to infected SARS-CoV-2 patients, providing fast answers regarding their infection status. Food and Drug Administration (FDA).

In-Vitro 52

In-Vitro Antibody Medicine Clinical Trials 52